{
  "landscapeName": "Approval Timelines",
  "displayKey": [
    "name",
    "originator_company",
    "drug_class"
  ],
  "iconsKey": [
    "roa",
    "development_status"
  ],
  "colorsKey": [
    "moa"
  ],
  "phases": {
    "Phase I": {
      "priority": 0,
      "assets": [
        {
          "id": "295",
          "brand_name": "BCD-055",
          "generic_name": "BS infliximab",
          "other_name": "",
          "name": "BCD-055",
          "originator_company": [
            "Biocad"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS infliximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Biocad has conducted Phase III trial of BCD-055 in Russia and filed the application with Russian Ministry of Health. Company states that they expect to launch the drug in 2018.<br \/><br \/>In November 2015, Biocad completed Phase 1 trial of BCD-055 in Belarus and Russia.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-TNF (BS infliximab)": "#66001d"
          }
        },
        {
          "id": "309",
          "brand_name": "DMB-3113",
          "generic_name": "BS adalimumab",
          "other_name": "",
          "name": "DMB-3113",
          "originator_company": [
            "DM Bio "
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Product is available for licensing except Japan and Korea.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "310",
          "brand_name": "GB232",
          "generic_name": "BS adalimumab",
          "other_name": "BCD-100",
          "name": "GB232",
          "originator_company": [
            "Genor Biopharma "
          ],
          "licensee_company": [
            "Biocnd"
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Phase I is ongoing in S. Korea and international multicenter phase III clinical trials will be carried out after the successful completion of this phase I trial.<br \/><br \/>Genor Biopharma has licensed out the South Asia, Southeast and Northeast Asia (except Greater China), and Russia right of GB232 (adalimumab biosimilar) to&nbsp;BIOCND.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "317",
          "brand_name": "MSB 11456",
          "generic_name": "BS tocilizumab",
          "other_name": "",
          "name": "MSB 11456",
          "originator_company": [
            "Merck KGaA"
          ],
          "licensee_company": [
            "Fresenius Kabi"
          ],
          "moa": [
            "IL-6 receptor antagonist (BS tocilizumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>In Sep'17, Merck KGaA announced the completion of the divestment of its biosimilars business to Fresenius in exchange for an upfront payment of &euro;156 M, milestone payments of up to &euro;500 M plus royalties on future product sales.<\/p>\r<\/li><li><p>The transaction comprises the entire development pipeline focused on oncology &amp; autoimmune disease, with most of the candidates in pre-clinical phase. The lead candidate is adalimumab biosimilar, in Phase III development. Merck KGaA and Fresenius also entered into a supply and service agreements, which include drug development support and manufacturing services. Fresenius Kabi will produce biosimilars at the Merck sites in Aubonne and Vevey, Switzerland.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "IL-6 receptor antagonist (BS tocilizumab)": "#966d6a"
          }
        },
        {
          "id": "318",
          "brand_name": "LusiNEX",
          "generic_name": "BS tocilizumab",
          "other_name": "",
          "name": "LusiNEX",
          "originator_company": [
            "Mycenax"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "IL-6 receptor antagonist (BS tocilizumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>In Oct'17, Mycenax Biotech announced that the Australian Government Department of Health has approved the phase I application for LusiNEX.<br \/><br \/>Mycenax Biotech also plans to conduct Phase I study in Europe.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "IL-6 receptor antagonist (BS tocilizumab)": "#966d6a"
          }
        },
        {
          "id": "319",
          "brand_name": "M834",
          "generic_name": "BS abatacept",
          "other_name": "",
          "name": "M834",
          "originator_company": [
            "Momenta "
          ],
          "licensee_company": [
            "Mylan"
          ],
          "moa": [
            "CD80\/ CD86 modulator (BS abatacept)"
          ],
          "drug_class": "Protein\/Peptide",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Momenta, in their Q3 2017 Earnings Call, announced that M834 (abatacept biosimilar) did not meet its primary PK endpoints in Phase I study. The study compared the PK, safety and immunogenicity of M834 to US and EU-sourced Orencia in normal healthy volunteers.<\/p>\r<\/li><li><p>Momenta is in the process of performing a comprehensive investigation into the potential reason for the PK results which could be anything from assay variations to structural differences. However, Mometa have no firm conclusions yet. After the finalization of investigation, Momenta will work with Mylan to determine next steps.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "CD80\/ CD86 modulator (BS abatacept)": "#193268"
          }
        }
      ],
      "color": {
        "background": "#333333",
        "color": "#ffffff"
      }
    },
    "Phase II": {
      "priority": 1,
      "assets": [
        {
          "id": "322",
          "brand_name": "PF-05280586",
          "generic_name": "BS rituximab",
          "other_name": "",
          "name": "PF-05280586",
          "originator_company": [
            "Pfizer"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-CD20 (BS rituximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>PF-05280586 has completed Phase III for Follicular Lymphoma and Phase I\/II for RA. Pfizer has also completed the extension <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01643928\" target=\"_blank\" rel=\"noopener\">REFLECTIONS B328-04<\/a> trial for Rheumatoid arthritis.<br \/><br \/>Pfizer recently announced that Phase III <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02213263\" target=\"_blank\" rel=\"noopener\">REFLECTIONS B3281006<\/a> met its primary endpoint, demonstrating equivalence in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-CD20 (BS rituximab)": "#53a819"
          }
        }
      ],
      "color": {
        "background": "#333333",
        "color": "#ffffff"
      }
    },
    "Phase III": {
      "priority": 2,
      "assets": [
        {
          "id": "286",
          "brand_name": "Remsima SC",
          "generic_name": "BS infliximab",
          "other_name": "CT-P13 SC",
          "name": "Remsima SC",
          "originator_company": [
            "Celltrion "
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS infliximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>In June 2017, Celltrion announced that the company is going ahead with its clinical trial plans for a SC version of Remsima (infliximab biosimilar) that will provide more-convenient self-administration option for patients and reduces hospital visits.<br \/><br \/>Currently, clinical trials are being conducted in Europe and South Korea. Celltrion expects that the study will meet endpoints earlier than the scheduled completion date and hope to receive approval and launch new SC formulation by Q1 2019.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS infliximab)": "#66001d"
          }
        },
        {
          "id": "294",
          "brand_name": "ABP 710",
          "generic_name": "BS infliximab",
          "other_name": "",
          "name": "ABP 710",
          "originator_company": [
            "Amgen"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS infliximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Per Q4 2017 earnings call, Amgen expects Phase 3 rheumatoid arthritis data from ABP 710 in H2 2018.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-TNF (BS infliximab)": "#66001d"
          }
        },
        {
          "id": "296",
          "brand_name": "BOW015",
          "generic_name": "BS infliximab",
          "other_name": "",
          "name": "BOW015",
          "originator_company": [
            "Epirus"
          ],
          "licensee_company": [
            "Reliance Life Sciences"
          ],
          "moa": [
            "anti-TNF (BS infliximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Clinical trial status is unknown<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "development_status": [
            {
              "name": "Status Doubtful",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/statusDoubtful.png"
            }
          ],
          "colors": {
            "anti-TNF (BS infliximab)": "#66001d"
          }
        },
        {
          "id": "303",
          "brand_name": "PF-06410293",
          "generic_name": "BS adalimumab",
          "other_name": "",
          "name": "PF-06410293",
          "originator_company": [
            "Pfizer"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><span>PF-06410293 is a monoclonal antibody (mAb) that is in being developed as a potential biosimilar to Humira.<br \/><br \/>In Jan 2017, Pfizer announed positive top-line results from\u00a0PF-06410293, Phase III (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02480153\" target=\"_blank\" rel=\"noopener\">REFLECTIONS B538-02)<\/a> study,\u00a0evaluating the efficacy, safety, and immunogenicity of PF-06410293 compared to Humira.<\/span><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "304",
          "brand_name": "M923",
          "generic_name": "BS adalimumab",
          "other_name": "BAX 2923",
          "name": "M923",
          "originator_company": [
            "Momenta "
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>During the JP Morgan Healthcare Conference 2018, Momenta announced that BLA filing for its adalimumab biosimilar (M923) has been delayed.&nbsp;The timing of filing depends on the identification of a collaboration partner which Momenta believes to happen somewhere in 2018. Earlier, the filing was planned for Q4&rsquo;17.<br \/><br \/>Moment believes that the recent global patent settlement between Amgen and AbbVie over adalimumab biosimilar probably set back launch of M923 to 2022-23.<br \/><br \/>No new update on expected EU filing is disclosed by the company.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "305",
          "brand_name": "MYL-1401A",
          "generic_name": "BS adalimumab",
          "other_name": "BMO 2",
          "name": "MYL-1401A",
          "originator_company": [
            "Biocon "
          ],
          "licensee_company": [
            "Mylan"
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Per company statement, filing is linked both to the regulatory as well as the IP status. The Amgen settlement guides for the launch in early 2023 in the US market.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "306",
          "brand_name": "CHS-1420",
          "generic_name": "BS adalimumab",
          "other_name": "",
          "name": "CHS-1420",
          "originator_company": [
            "Coherus "
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>In line with the negative '619 IPR outcomes, company redirected their focus on securing a adalimumab biosimilar launch when certain formulation patents expire in H2 2022.<br \/><br \/>Company reiterated that they will continue to optimize the manufacturing of CHS-1420.<br \/><br \/>Coherus redirected some of the intended spend for their adalimumab biosimilar towards the ophthalmology program.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "307",
          "brand_name": "ONS-3010",
          "generic_name": "BS adalimumab",
          "other_name": "",
          "name": "ONS-3010",
          "originator_company": [
            "Oncobiologics"
          ],
          "licensee_company": [
            "Zhejiang Huahai"
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Oncobiologics have an arrangement with Zhejiang Huahai Pharmaceutical for the co-development and joint commercialization of ONS-3010 in certain major developed markets, including the US and EU.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "308",
          "brand_name": "LBAL",
          "generic_name": "BS adalimumab",
          "other_name": "",
          "name": "LBAL",
          "originator_company": [
            "LG Chem "
          ],
          "licensee_company": [
            "Mochida"
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Collaboration with Mochida Pharmaceutical in Japan<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "313",
          "brand_name": "CHS-0214",
          "generic_name": "BS etanercept",
          "other_name": "BAX 2200",
          "name": "CHS-0214",
          "originator_company": [
            "Coherus "
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS etanercept)"
          ],
          "drug_class": "Protein\/Peptide",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Coherus stated that they will focus the development and IP strategy of CHS-0214 in more attractive US market.<\/p>\r<\/li><li><p>Coherus has conducted clinical trials in both PSO and RA patients.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS etanercept)": "#802d63"
          }
        },
        {
          "id": "314",
          "brand_name": "YLB113",
          "generic_name": "BS etanercept",
          "other_name": "",
          "name": "YLB113",
          "originator_company": [
            "YL Biologics "
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS etanercept)"
          ],
          "drug_class": "Protein\/Peptide",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>YL Biologics is the joint venture of Lupin and Yoshindo. Lupin is looking for the distribution partner in the major markets.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS etanercept)": "#802d63"
          }
        },
        {
          "id": "320",
          "brand_name": "ABP 798",
          "generic_name": "BS rituximab",
          "other_name": "",
          "name": "ABP 798",
          "originator_company": [
            "Amgen"
          ],
          "licensee_company": [
            "Allergan"
          ],
          "moa": [
            "anti-CD20 (BS rituximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>In December 2011, Amgen and Allergan (then Watson Pharmaceuticals) formed a collaboration to develop and commercialize, on a worldwide basis, four oncology antibody biosimilar medicines,including ABP 798.<br \/><br \/>Amgen is developing ABP 798 in collaboration with Allergan for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-CD20 (BS rituximab)": "#53a819"
          }
        },
        {
          "id": "324",
          "brand_name": "SAIT-101",
          "generic_name": "BS rituximab",
          "other_name": "",
          "name": "SAIT-101",
          "originator_company": [
            "Archigen Biotech"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-CD20 (BS rituximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Archigen Biotech is a 50-50 joint venture between Samsung BioLogics and AstraZeneca.<br \/><br \/>In addition to Korea, Archigen Biotech has been conducting clinical trials of SAIT101 in the US since July 2016. Once the drug gains regulatory approval by the US FDA, AstraZeneca is set to take charge of SAIT101&rsquo;s marketing and sales in the US.<\/p>\r<\/li><li><p>Samsung BioLogics is also planning to launch SAIT101, its biosimilar version of Rituxan, however the timeline is not known.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-CD20 (BS rituximab)": "#53a819"
          }
        },
        {
          "id": "325",
          "brand_name": "MabionCD20",
          "generic_name": "BS rituximab",
          "other_name": "",
          "name": "MabionCD20",
          "originator_company": [
            "Mabion"
          ],
          "licensee_company": [
            "Mylan"
          ],
          "moa": [
            "anti-CD20 (BS rituximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>In Sep'17, company reported positive results of the clinical trial regarding MabionCD20 in RA. Based on this data,&nbsp;Mabion plans to submit Marketing Authorization Application to EMA in Q1 of 2018, followed by negotiations with the US FDA.<br \/><br \/>In 2016, Mabion signed a long-term development and commercialization agreement with Mylan to sell Mabion&rsquo;s biosimilar of Mabthera\/Rituximab (Mabion CD20) in all EU countries and non EU Balkan states. Mylan will support Mabion to secure approval of Mabion CD20 by the European Medicine Agency.<\/p>\r<\/li><li><p>&nbsp;<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-CD20 (BS rituximab)": "#53a819"
          }
        },
        {
          "id": "326",
          "brand_name": "BCD-020",
          "generic_name": "BS rituximab",
          "other_name": "Acellbia, USMAL",
          "name": "BCD-020",
          "originator_company": [
            "Biocad"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-CD20 (BS rituximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>BIOCAD&rsquo;s rituximab has already been authorized in seven countries, including Bolivia and Honduras, with the registration pending in 27 countries for cancer.<br \/><br \/>In Oct 2017, the Russian government&rsquo;s Chamber for Patent Disputes announced that Roche&ndash;Genentech&rsquo;s patent covering the use of rituximab in rheumatoid arthritis was invalid.<br \/><br \/>Biocad announced its intentions to enter the European marketplace with both its innovator and biosimilar products, and said that it expects to receive marketing authorization from the European Medicines Association beginning in 2021.<br \/><br \/><\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-CD20 (BS rituximab)": "#53a819"
          }
        },
        {
          "id": "327",
          "brand_name": "RGB-03",
          "generic_name": "BS rituximab",
          "other_name": "",
          "name": "RGB-03",
          "originator_company": [
            "Gedeon Richter"
          ],
          "licensee_company": [
            "Stada"
          ],
          "moa": [
            "anti-CD20 (BS rituximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Acc to Stada's Oct 2016 report, company expects to launch rituximab biosimilar by 2019.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-CD20 (BS rituximab)": "#53a819"
          }
        }
      ],
      "color": {
        "background": "#333333",
        "color": "#ffffff"
      }
    },
    "Filed": {
      "priority": 3,
      "assets": [
        {
          "id": "289",
          "brand_name": "GP1111",
          "generic_name": "BS infliximab",
          "other_name": "PF 6438179",
          "name": "GP1111",
          "originator_company": [
            "Pfizer"
          ],
          "licensee_company": [
            "Sandoz"
          ],
          "moa": [
            "anti-TNF (BS infliximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p><span>In Mar'18, Sandoz received Positive CHMP Opinion for proposed biosimilar Infliximab (GP1111).<\/span><br \/><br \/>Sandoz regulatory submission for proposed biosimilar infliximab accepted by EMA in May 2017, with approval anticipated in Q2 2018.<br \/><br \/>In February 2016, Sandoz acquired the rights from Pfizer for the development, commercialization and manufacture of PF-06438179 in the 31 countries that form the European Economic Area (EEA) where it is known as GP1111. Pfizer retains commercialization and manufacturing rights to infliximab in all countries outside of the EEA.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-TNF (BS infliximab)": "#66001d"
          }
        },
        {
          "id": "300",
          "brand_name": "GP2017",
          "generic_name": "BS adalimumab",
          "other_name": "",
          "name": "GP2017",
          "originator_company": [
            "Sandoz"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Sandoz regulatory submission for GP2017 has been accepted by FDA (Jan'18) and EMA (May'17). Approval in Europe is anticipated by mid-2018.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "301",
          "brand_name": "FKB327",
          "generic_name": "BS adalimumab",
          "other_name": "",
          "name": "FKB327",
          "originator_company": [
            "Fujifilm Kyowa Kirin Biologics "
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Fujifilm's FKB327 is currently under regulatory review in EU (MAA accepted in May 2017). Approval is anticipated in Q2 2018.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "302",
          "brand_name": "MSB-11022",
          "generic_name": "BS adalimumab",
          "other_name": "",
          "name": "MSB-11022",
          "originator_company": [
            "Merck KGaA"
          ],
          "licensee_company": [
            "Fresenius Kabi"
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>In Dec'17, Fresenius announced the acceptance of MAA by the EMA. The filing was based on the results of the Phase III <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02660580\" target=\"_blank\" rel=\"noopener\">AURIEL-PSO<\/a> study showing equivalent efficacy of MSB11022 to the Humira. EU approval is anticipated in Q4 2018.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        }
      ],
      "color": {
        "background": "#333333",
        "color": "#ffffff"
      }
    },
    "Approved": {
      "priority": 4,
      "assets": [
        {
          "id": "287",
          "brand_name": "Renflexis\/ Flixabi",
          "generic_name": "BS infliximab",
          "other_name": "SB2",
          "name": "Renflexis\/ Flixabi",
          "originator_company": [
            "Samsung Bioepis"
          ],
          "licensee_company": [
            "Biogen, Merck & Co."
          ],
          "moa": [
            "anti-TNF (BS infliximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Samsung's infliximab biosimilar was approved under the brand name \"Flixabi\" in EU in Q2 0216 and as \"Renflexis\" in the US in Q2 2017.<br \/><br \/><span>Merck &amp; Co. is responsible for the commercialization of Renflexis WW, excluding EU, Switzerland, Russia &amp; Turkey, where Biogen markets the product under the brand name \"Flixabi.\"<\/span><\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-TNF (BS infliximab)": "#66001d"
          }
        },
        {
          "id": "288",
          "brand_name": "IXIFI",
          "generic_name": "BS infliximab",
          "other_name": "PF 6438179",
          "name": "IXIFI",
          "originator_company": [
            "Pfizer"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS infliximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Ixifi was approved in the US in Q4 2017, however, Pfizer has no plans to launch it in the US at this time due to conflict with Inflectra and is evaluating strategic options for this product.<\/p>\r<\/li><li><p>In February 2016, Sandoz acquired the rights from Pfizer for the development, commercialization and manufacture of PF-06438179 in the 31 countries that form the European Economic Area (EEA) where it is known as GP1111. Pfizer retains commercialization and manufacturing rights to infliximab in all countries outside of the EEA.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-TNF (BS infliximab)": "#66001d"
          }
        },
        {
          "id": "293",
          "brand_name": "Inflectra\/ Remsima",
          "generic_name": "BS infliximab",
          "other_name": "CT-P13",
          "name": "Inflectra\/ Remsima",
          "originator_company": [
            "Celltrion "
          ],
          "licensee_company": [
            "Pfizer"
          ],
          "moa": [
            "anti-TNF (BS infliximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Remsima received first approval in EU in Q3 2016 followed by Japan (Q3 2014) and USA (Q2 2016). Pfizer markets CT-P13 under the brand Inflectra in the US and EU, whereas, Celltrion markets CT-P13 under the brand name Remsima in EU and RoW.<\/p>\r<\/li><li><p>Celltrion has entered into the partnership with local players for the distribution of Remsima. e.g. Mundi Pharma (Germany, Italy, UK, Netherlands, Belgium &amp; Luxembourg), Orion Pharma (Sweden), Nippon Kayaku (Japan), Biogaran (France) and Kern Pharmaceutical (Spain).<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-TNF (BS infliximab)": "#66001d"
          }
        },
        {
          "id": "297",
          "brand_name": "Amgevita\/ Amjevita",
          "generic_name": "BS adalimumab",
          "other_name": "ABP-501, Solymbic",
          "name": "Amgevita\/ Amjevita",
          "originator_company": [
            "Amgen"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Amgen's adalimumab biosimilar was approved in the US as Amjevita in Q3 2016 and in EU as Amgevita in Q1 2017. The launch has been delayed due to patent considerations.<br \/><br \/>In September 2017, Amgen reached a global settlement with AbbVie to resolve all pending litigation regarding Amgevita. Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of Amgevita worldwide, on a country-by-country basis. Amgen expects to launch Amgevita in Europe in October 2018 and Amjevita in the United States in January 2023.<\/p>\r<\/li><li><p>Amgen and Japan-based Daiichi Sankyo announced on 13 July 2016 that they had made an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "298",
          "brand_name": "Imraldi",
          "generic_name": "BS adalimumab",
          "other_name": "SB5",
          "name": "Imraldi",
          "originator_company": [
            "Samsung Bioepis"
          ],
          "licensee_company": [
            "Biogen, Merck & Co."
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Imraldi received EU approval in Q3 2017. Biogen will be responsible for its marketing in EU. Launch has been delayed due to patent considerations.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "299",
          "brand_name": "Cyltezo",
          "generic_name": "BS adalimumab",
          "other_name": "",
          "name": "Cyltezo",
          "originator_company": [
            "Boehringer Ingelheim"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS adalimumab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Cyltezo was first approved in the US in Q3 2017 followed by EU approval in Q4 2017. Launch has been delayed due to patent considerations.<br \/><br \/>Boehringer Ingelheim is also conducitng an additional study (VOLTAIRE-X) to demonstrate interchangeability between its adalimumab biosimilar candidate and Humira.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS adalimumab)": "#e23353"
          }
        },
        {
          "id": "311",
          "brand_name": "Erelzi",
          "generic_name": "BS etanercept",
          "other_name": "GP2015",
          "name": "Erelzi",
          "originator_company": [
            "Sandoz"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS etanercept)"
          ],
          "drug_class": "Protein\/Peptide",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Erelzi (etanercept biosimilar) recevied EU approval in Q2 2017. In Q3 2017 earning calls, Novartis reported that Erelzi received good feedback from customers and patients and won major accounts in EU e.g. UK.<br \/><br \/>Although approved in the US in Q3 2016, Sandoz disclosed that it will not go on sale before 2018 at the earliest because of the patent protection challenge by Amgen. Amgen is arguing in US federal court that the original product, Enbrel, has patent protection until 2029.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS etanercept)": "#802d63"
          }
        },
        {
          "id": "312",
          "brand_name": "Benepali",
          "generic_name": "BS etanercept",
          "other_name": "SB4, Brenzys",
          "name": "Benepali",
          "originator_company": [
            "Samsung Bioepis"
          ],
          "licensee_company": [
            "Biogen, Merck & Co."
          ],
          "moa": [
            "anti-TNF (BS etanercept)"
          ],
          "drug_class": "Protein\/Peptide",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Benepali received EU approval in Q1 2016. Biogen is responsible for its marketing in the EU.<br \/><br \/>Biogen is conducting an observational study to assess Benepali PEN patient satisfaction in 500 participants (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03327454\" target=\"_blank\" rel=\"noopener\">NCT03327454<\/a>).<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS etanercept)": "#802d63"
          }
        },
        {
          "id": "315",
          "brand_name": "Etanercept BS [MA]",
          "generic_name": "BS etanercept",
          "other_name": "LBEC0101",
          "name": "Etanercept BS [MA]",
          "originator_company": [
            "LG Chem "
          ],
          "licensee_company": [
            "Mochida"
          ],
          "moa": [
            "anti-TNF (BS etanercept)"
          ],
          "drug_class": "Protein\/Peptide",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Mochida has in-licensed LBEC0101 from LG Life Sciences for the Japanese market. Product recevied Japanese regulatory approval in Q1 2018.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS etanercept)": "#802d63"
          }
        },
        {
          "id": "316",
          "brand_name": "Lifmior",
          "generic_name": "BS etanercept",
          "other_name": "",
          "name": "Lifmior",
          "originator_company": [
            "Pfizer"
          ],
          "licensee_company": [
            
          ],
          "moa": [
            "anti-TNF (BS etanercept)"
          ],
          "drug_class": "Protein\/Peptide",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Pfizer obtained approval for copy version of Enbrel in EU in Q1 2017.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "SC",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png"
            }
          ],
          "colors": {
            "anti-TNF (BS etanercept)": "#802d63"
          }
        },
        {
          "id": "321",
          "brand_name": "Rixathon",
          "generic_name": "BS rituximab",
          "other_name": "GP 2013, Riximyo",
          "name": "Rixathon",
          "originator_company": [
            "Sandoz"
          ],
          "licensee_company": [
            "Kyowa Hakko Kirin"
          ],
          "moa": [
            "anti-CD20 (BS rituximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>In May 2018,\u00a0Sandoz announced that they have received complete response letter from the US FDA for proposed biosimilar rituximab.\u00a0While disappointed, Sandoz remains committed to further discussions with FDA in order to bring this medicine to US patients (<a href=\"https:\/\/www.sandoz.com\/news\/media-releases\/sandoz-receives-complete-response-letter-us-fda-proposed-biosimilar-rituximab\" target=\"_blank\" rel=\"noopener\">Link<\/a>)<br \/><br \/>Rixathon has already been approved in EU (Q2 2017) and Japan (Q3 2017)<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-CD20 (BS rituximab)": "#53a819"
          }
        },
        {
          "id": "323",
          "brand_name": "Truxima",
          "generic_name": "BS rituximab",
          "other_name": "CT-P10",
          "name": "Truxima",
          "originator_company": [
            "Celltrion "
          ],
          "licensee_company": [
            "Teva"
          ],
          "moa": [
            "anti-CD20 (BS rituximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>Truxima was approved by the European Commission in February 2017 and has been launched in major EU markets including U.K., Germany, Netherlands, Spain etc.<br \/><br \/>US FDA has accepted the BLA for CT-P10 in June'17. Regulatory approval anticipated in Q2 2018.<br \/><br \/>Celltrion and Teva entered into an exclusive partnership to commercialize CT-P10 (rituximab biosimilar) and CT-P6 (trastuzumab biosimilar) in the US and Canada in October 2016. As part of the agreement, Teva is responsible for all commercial activities while Celltrion has responsibility for completing all clinical development and regulatory activities.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-CD20 (BS rituximab)": "#53a819"
          }
        },
        {
          "id": "328",
          "brand_name": "Infliximab BS \"Nichi-Iko\"",
          "generic_name": "BS infliximab",
          "other_name": "GS 071, NI-071",
          "name": "Infliximab BS \"Nichi-Iko\"",
          "originator_company": [
            "Nichi-Iko"
          ],
          "licensee_company": [
            "Aprogen"
          ],
          "moa": [
            "anti-TNF (BS infliximab)"
          ],
          "drug_class": "mAb",
          "developmentphase_comment": "",
          "other_comments": "<ul><li><p>In Sep'17, Nichi-Iko Pharmaceutical announced that it had gained approval for its infliximab biosimilar in Japan. The biosimilar infliximab will be jointly marketed in Japan by ZERIA Pharmaceutical.<br \/><br \/>Phase III trial (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02990806\" target=\"_blank\" rel=\"noopener\">RADIANCE<\/a>) in the US is currently ongoing and is designed to interchnageability. Nichi-Iko Pharmaceutical expects US filing in 2019 and regulatory approval in 2021. Following approval in the US, marketing will be carried out by Nichi-Iko\u2019s US subsidiary Sagent Pharmaceuticals.<\/p><\/li><\/ul>",
          "roa": [
            {
              "name": "IV",
              "iconPath": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png"
            }
          ],
          "colors": {
            "anti-TNF (BS infliximab)": "#66001d"
          }
        }
      ],
      "color": {
        "background": "#333333",
        "color": "#ffffff"
      }
    }
  },
  "legends": {
    "colors": {
      "anti-TNF (BS infliximab)": "#66001d",
      "anti-TNF (BS adalimumab)": "#e23353",
      "IL-6 receptor antagonist (BS tocilizumab)": "#966d6a",
      "CD80\/ CD86 modulator (BS abatacept)": "#193268",
      "anti-CD20 (BS rituximab)": "#53a819",
      "anti-TNF (BS etanercept)": "#802d63"
    },
    "icons": {
      "IV": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/iv.png",
      "SC": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/sc.png",
      "Status Doubtful": "ciportal-sanofi.com\/assets\/7916dc47\/images\/genzyme\/statusDoubtful.png"
    }
  },
  "subfilters": {
    "326": "anti-TNF (BS infliximab)",
    "327": "anti-TNF (BS adalimumab)",
    "330": "IL-6 receptor antagonist (BS tocilizumab)",
    "331": "CD80\/ CD86 modulator (BS abatacept)",
    "329": "anti-CD20 (BS rituximab)",
    "328": "anti-TNF (BS etanercept)"
  },
  "viewMode": "phase"
}